May 21,2024

Glooko Announces Presidents of Life Sciences and Connected Care

Glooko announces the appointments of Dr. David Pass and Adam Hameed as Presidents of Life Sciences and Connected Care, respectively. With the evolving landscape of healthcare technology and increasing demand for personalized care, these new roles underscore Glooko’s commitment to driving advancements not only in health systems, but also across the life sciences space, specifically: digital companions/therapeutics, clinical research, real-world data and device integrations.

View Analyst & Ambassador Comments
Go to original news
May 22,2024 TOP STORY

Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics

Click Therapeutics announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc. The assets acquired include AspyreRx (BT-001), the first FDA-authorized prescription digital therapeutic for type 2 diabetes, and BT-004, which was recently granted FDA Breakthrough Device Designation for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Other assets are BT-002, for the reduction of blood pressure in patients with hypertension, and BT-003, for the reduction of LDL cholesterol in patients with hyperlipidemia. This acquisition strengthens Click’s portfolio of innovative digital treatments for patients by immediately advancing its pipeline in obesity, diabetes and cardiometabolic diseases, complementing existing assets in psychiatry, CNS and pain disorders. Integration of Better Therapeutics’ intellectual property with Click’s development plans for obesity is expected to both accelerate development timelines and yield a best-in-class digital therapy for chronic weight management.

COLLABORATION MERGERS & ACQUISITION

#product & service

#dtx

View Analyst & Ambassador Comments
Go to original news
May 14,2024

Vida Health Collaborates with OUTRIGGER Resorts & Hotels to Enhance Employee Benefits with Innovative Diabetes Management Program

Vida Health has partnered with OUTRIGGER Resorts & Hotels to enhance OUTRIGGER’s employee benefits with personalized diabetes management solutions. This program, called Chronic Pathway, provides individualized care plans, medical nutrition therapy, medication management, and remote patient monitoring for eligible employees. Vida Health's CEO, Joe Murad, emphasized the program's innovative approach to improving employees' health outcomes.

PRODUCT

#virtual care

#rpm

#coaching

View Analyst & Ambassador Comments
Go to original news
May 16,2024

Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI

Trinity Biotech has partnered with PulseAI to enhance its continuous glucose monitor (CGM) technology with AI-driven health and wellness analytics. Trinity Biotech will provide unique CGM datasets to PulseAI, who will use this data to develop an AI platform for Trinity’s CGM solution. This collaboration aims to create a needle-free, reusable diabetes management solution with superior metabolic insights. Both companies see this partnership as a step towards improved glucose monitoring and broader health analytics.

COLLABORATION PARTNERSHIP

#r&d

#cgm

View Analyst & Ambassador Comments
Go to original news
May 16,2024

GLUCOTRACK’S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDY

GlucoTrack, Inc. has announced successful results from the first 30 days of a 60-day preclinical study for its implantable continuous glucose monitor, which measures glucose levels in the epidural space. The study showed that the sensor accurately tracked blood glucose levels and a commercially available subcutaneous CGM in animals, with no complications observed. This device aims to simplify disease management for patients with painful diabetic neuropathy. The study will continue to assess the long-term performance of the sensor. If approved, this technology could significantly benefit the millions of people with diabetes affected by neuropathy. The 60-day long-term study is ongoing, with periodic glucose tolerance testing to compare the performance of the Glucotrack epidural sensor performance against blood glucose and subcutaneous CGM.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 09,2024

Welldoc Named “Best Overall Digital Health Company” for Second Consecutive Year in the 8th Annual MedTech Breakthrough Awards Program

Welldoc has won the "Best Overall Digital Health Company" award for the second consecutive year in the 8th annual MedTech Breakthrough Awards. The company's AI-powered platform offers flexible, multi-condition digital coaching across various health issues like diabetes, weight management, hypertension, heart failure, and prediabetes. It also provides personalized insights to empower individuals to manage their health better and offers critical data for clinical decision-making.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
May 09,2024 TOP STORY

Senseonics, Rimidi partner on remote diabetes monitoring program

Senseonics has partnered with Rimidi to develop a remote patient monitoring (RPM) program utilizing Senseonics' Eversense continuous glucose monitor (CGM). The Eversense CGM, known for its long wear time and accuracy, recently received FDA approval for integration with insulin pumps. The RPM program, expected to launch by the third quarter of 2024, aims to optimize diabetes management between office visits. It will integrate Eversense glucose data into Rimidi's clinical management platform, facilitating remote monitoring aligned with Medicare's reimbursable telehealth programs. The collaboration seeks to improve patient engagement, drive workflow optimization, and provide clinical decision support, ultimately enhancing diabetes outcomes and reducing healthcare costs.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#rpm

View Analyst & Ambassador Comments
Go to original news
May 09,2024

Medtronic to announce financial results for its fourth quarter and full fiscal year 2024

Medtronic announced that it will report financial results for its fourth quarter and full fiscal year 2024 on Thursday, May 23, 2024. They will host a video webcast at 7:00 a.m. CDT on Thursday, May 23, 2024, to discuss results for its fourth quarter and full fiscal year 2024. The webcast can be accessed at https://investorrelations.medtronic.com.

View Analyst & Ambassador Comments
Go to original news
May 10,2024

Glucose levels measured with continuous glucose monitoring in uncomplicated pregnancies

This clinical study aimed to characterize glucose levels during uncomplicated pregnancies, defined as pregnancies with normal A1c levels in early pregnancy and without complications like large-for-gestational-age birth or gestational diabetes. A total of 413 pregnant individuals wore Dexcom G6 continuous glucose monitoring (CGM) devices throughout their pregnancy. Results showed stable glucose levels throughout all trimesters, with an overall mean glucose level of 98 mg/dL. Most time was spent within the target range of 63-120 mg/dL, with rare instances of levels above 140 mg/dL. Post-prandial peak glucose was 126 mg/dL on average. Higher mean glucose levels were associated with higher body mass index (BMI). These findings provide insight into glucose levels during uncomplicated pregnancies and can inform treatment targets for pregnant individuals.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 09,2024

Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery

Arecor Therapeutics announced a research collaboration with Medtronic to develop a novel, high concentration, thermostable insulin for use by Medtronic’s Diabetes business in a next-generation implantable pump. This new insulin has the potential to bring significant advancements in the current insulin treatment options for a small population of patients who have limited options for controlling their diabetes with traditional therapy. This collaboration has the potential to allow for the continued care of these patients with an insulin that may minimise the need for pump maintenance interventions and expand the utility for physicians, whilst saving healthcare costs.

COLLABORATION PARTNERSHIP

#r&d

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES